Chong Kun Dang Pharmaceutical Corp.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
Phase 1
Completed
- Conditions
- Cardiovascular Diseases
- Interventions
- Drug: Reference drugDrug: Test drug 1Drug: Test drug 2
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT04083846
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-385 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Cardiovascular Diseases
- Interventions
- Drug: Reference drugDrug: Test drug
- First Posted Date
- 2019-09-03
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 52
- Registration Number
- NCT04075643
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of
Efficacy and Safety of Once-Daily Tacrolimus in Liver Transplant Recipients (SOUL)
Phase 4
- Conditions
- Liver Transplant
- Interventions
- Drug: Conversion to Once-daily Tacrolimus
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 146
- Registration Number
- NCT04069065
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
A Clinical Study to Compare the Safety and Pharmacokinetics of CKD-320 and D012
Phase 1
- Conditions
- Hypertension
- Interventions
- Drug: CKD-320, D012
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 42
- Registration Number
- NCT04035538
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers
Phase 1
Completed
- Conditions
- HypertensionDyslipidemias
- Interventions
- Drug: CKD-330 16/10mg Tab. 1T and D086 Tab. 1TDrug: CKD-333 16/10/40mg formulation 1 Tab. 1TDrug: CKD-333 16/10/40mg formulation 2 Tab. 1T
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT04019743
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, South Korea, Korea, Republic of
A Clinical Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 162
- Registration Number
- NCT03950843
- Locations
- 🇰🇷
Jong-ll, Seoul, Korea, Republic of
Clinical Trial to Evaluate the Efficacy and Safety of EsoDuo Tab. 20/800mg
Phase 4
Completed
- Conditions
- Non-erosive Reflux Disease(NERD)
- Interventions
- Drug: EsoDuo Tab. 20/800mg
- First Posted Date
- 2019-04-26
- Last Posted Date
- 2019-12-24
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 379
- Registration Number
- NCT03928470
- Locations
- 🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷Kosin University Gospel Hospital, Busan, Korea, Republic of
🇰🇷Hallym University Chuncheon Seonsim Hospital, Chuncheon, Korea, Republic of
A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male Volunteers
Phase 1
- Conditions
- HypertensionDyslipidemias
- Interventions
- Drug: CKD-386 formulation 1Drug: CKD-386 formulation 2Drug: D326, D337 and D013
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT03920579
- Locations
- 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers
Phase 1
Completed
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Drug: Harnal-D Tab.Drug: Chong Kun Dang Tamsulosin HCl Tab.
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT03887858
- Locations
- 🇰🇷
Bestian Hospital, Osong, Korea, Republic of
Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers After Meal
Phase 1
Completed
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Drug: Harnal-D Tab.Drug: Chong Kun Dang Tamsulosin HCl Tab.
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT03887871
- Locations
- 🇰🇷
Bestian Hospital, Osong, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath